Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBIT Margin (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EBIT Margin data on record, last reported at 11.94% in Q3 2025.

  • For Q3 2025, EBIT Margin fell 1029.0% year-over-year to 11.94%; the TTM value through Sep 2025 reached 10.3%, up 4877.0%, while the annual FY2024 figure was 7.34%, 459.0% up from the prior year.
  • EBIT Margin reached 11.94% in Q3 2025 per PLX's latest filing, up from 7.48% in the prior quarter.
  • Across five years, EBIT Margin topped out at 104.85% in Q4 2021 and bottomed at 142.62% in Q2 2021.
  • Average EBIT Margin over 5 years is 23.21%, with a median of 18.24% recorded in 2023.
  • Peak YoY movement for EBIT Margin: plummeted -13381bps in 2022, then soared 17571bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 104.85% in 2021, then plummeted by -128bps to 28.95% in 2022, then plummeted by -370bps to 136.14% in 2023, then surged by 129bps to 39.57% in 2024, then tumbled by -70bps to 11.94% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 11.94% in Q3 2025, 7.48% in Q2 2025, and 40.99% in Q1 2025.